American Journal of Cardiology
Volume 103, Issue 3 , Pages 381-386 , 1 February 2009

Ten-Year All-Cause Mortality in Presumably Healthy Subjects on Lipid-Lowering Drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort)

  • Virginie Gardette, MD

      Affiliations

    • INSERM U558, Department of Epidemiology, Health Economics and Public Health, Toulouse University School of Medicine, Toulouse, France
    • ,
  • Vanina Bongard, MD

      Affiliations

    • INSERM U558, Department of Epidemiology, Health Economics and Public Health, Toulouse University School of Medicine, Toulouse, France
    • ,
  • Jean Dallongeville, MD

      Affiliations

    • INSERM U744, Institut Pasteur de Lille, Lille, France
    • ,
  • Dominique Arveiler, MD

      Affiliations

    • Department of Epidemiology and Public Health, Louis Pasteur University, Strasbourg, France
    • ,
  • Annie Bingham, MA

      Affiliations

    • INSERM U909, Paul Brousse Hospital, Villejuif, France
    • ,
  • Jean-Bernard Ruidavets, MD

      Affiliations

    • INSERM U558, Department of Epidemiology, Health Economics and Public Health, Toulouse University School of Medicine, Toulouse, France
    • ,
  • Philippe Amouyel, MD

      Affiliations

    • INSERM U744, Institut Pasteur de Lille, Lille, France
    • ,
  • Bernadette Haas, MD

      Affiliations

    • Department of Epidemiology and Public Health, Louis Pasteur University, Strasbourg, France
    • ,
  • Pierre Ducimetière, PhD

      Affiliations

    • INSERM U909, Paul Brousse Hospital, Villejuif, France
    • ,
  • Jean Ferrières, MD

      Affiliations

    • INSERM U558, Department of Epidemiology, Health Economics and Public Health, Toulouse University School of Medicine, Toulouse, France
    • Department of Cardiology, Toulouse-Rangueil University Hospital, Toulouse, France
    • Corresponding Author InformationCorresponding author: Tel: +33-561-521-870; fax: +33-561-145-627

Received 12 August 2008 ,Revised 25 September 2008 ,Accepted 25 September 2008.

References 

  1. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  2. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–1630
  3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels (Cholesterol And Recurrent Events Trial investigators). N Engl J Med. 1996;335:1001–1009
  4. MRC/BHF Heart Protection Study Collaborative Group. Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  5. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74–80
  6. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–1356
  7. Ducimetiere P, Ruidavets JB, Montaye M, Haas B, Yarnell J. Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50–59 in France and Northern Ireland: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study. Int J Epidemiol. 2001;30:1057–1062
  8. Empana JP, Ducimetiere P, Arveiler D, Ferrieres J, Evans A, Ruidavets JB, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? (The PRIME Study). Eur Heart J. 2003;24:1903–1911
  9. Yarnell JW. The PRIME study: classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland (Prospective Epidemiological Study of Myocardial Infarction). QJM. 1998;91:667–676
  10. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project (Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents). Circulation. 1994;90:583–612
  11. Marques-Vidal P, Ruidavets JB, Cambou JP, Ferrieres J. Trends in the prevalence, awareness and treatment of hypercholesterolemia in South-western France, 1985–1997. CVD Prev. 2000;3:18–25
  12. National Cholesterol Education Program Expert Panel Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143–3421
  13. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007;357:1477–1486
  14. WHO. Cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up (Report of the Committee of Principal Investigators). Lancet. 1980;2:379–385
  15. The Bezafibrate Infarction Prevention Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation. 2000;102:21–27
  16. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861
  17. Tenkanen L, Manttari M, Kovanen PT, Virkkunen H, Manninen V. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med. 2006;166:743–748
  18. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease (A pooled meta-analysis of long-term randomized placebo-controlled clinical trials). Am Heart J. 2007;154:943–953
  19. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA. 1996;275:55–60
  20. Sleijfer S, van der Gaast A, Planting AS, Stoter G, Verweij J. The potential of statins as part of anti-cancer treatment. Eur J Cancer. 2005;41:516–522
  21. Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst. 2008;100:134–139
  22. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer. 2007;120:833–843
  23. Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2004;364:771–777

PII: S0002-9149(08)01709-8

doi: 10.1016/j.amjcard.2008.09.092

American Journal of Cardiology
Volume 103, Issue 3 , Pages 381-386 , 1 February 2009

Article Tools

* Image Usage & Resolution